AvalehtPRE • NASDAQ
add
Prenetics Global Ltd
Viimane sulgemishind
4,50 $
Tänane vahemik
4,43 $ - 4,43 $
Aasta vahemik
2,85 $ - 7,84 $
Turuväärtus
53,16 mln USD
Keskmine maht
6,93 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | juuni 2024info | Y/Y muutus |
---|---|---|
Käive | 5,94 mln | 4,32% |
Põhitegevusega seonduv kulu | 14,38 mln | 0,52% |
Puhastulu | −10,72 mln | 50,83% |
Puhaskasumimarginaal | −180,46 | 52,87% |
Puhaskasum aktsia kohta | — | — |
EBITDA | −9,51 mln | 13,59% |
Tõhus maksumäär | 0,79% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | juuni 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 63,89 mln | −67,46% |
Kogu vara | 233,31 mln | −16,93% |
Kõik kohustused | 42,30 mln | −30,22% |
Kogu omakapital | 191,00 mln | — |
Emiteeritud aktsiate arv | 12,22 mln | — |
Hinna ja väärtuse suhe P/B | 0,29 | — |
Varade tasuvus | −11,12% | — |
Kapitali tasuvus | −13,33% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | juuni 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −10,72 mln | 50,83% |
Põhitegevuse rahakäive | — | — |
Investeeringute raha | — | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | — | — |
Tasuta rahavoog | — | — |
Teave
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Asutatud
2014
Veebisait
Töötajate arv
322